ASPO Abstracts
Cardiometabolic Health of Ovarian Cancer Survivors Enrolled in GOG/NRG 0225 Randomized Controlled Trial of Diet and Physical Activity
Category: Lifestyles Behavior, Energy Balance & Chemoprevention
Conference Year: 2019
Abstract Body:
Purpose: The Lifestyle Intervention for oVarian cancer Enhanced Survival (LIVES) study GOG/NRG 0225 is testing the hypothesis that ovarian cancer survivors randomized to a diet and physical activity intervention for a period of 24-months will have longer progression-free survival than survivors randomized to a health education control condition. The purpose of this analysis was to determine the frequency of abnormal metabolic biomarkers in this sample of women who completed cancer treatment within 6 weeks to 6.5 months of study enrollment and were disease-free. Methods: Biomarkers analyzed included cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, insulin, glucose and high sensitivity C-reactive protein (hsCRP) using enzymatic colormetric method for lipids, enzymatic reference method with hexokinase for glucose and insulin and immunoassay for hsCRP. Descriptive statistics reporting averages and frequencies were performed. Results: At enrollment, the mean age was 59.3 y, 94.5% were Non-Hispanic White, and average body mass index was 27.9, with 29% classified as obese. Biomarker analysis at baseline on a sub-sample of 390 women, showed mean cardiometabolic indices of: cholesterol 96 ± 24 mg/dL, HDL 56 ± 16 mg/dL, LDL 122 ± 39 mg/dL, Triglycerides 136 ± 78 mg/dL, insulin 16.2 ± 23.2 mIU/L, glucose 96 ± 24 mg/dL, and hsCRP of 4.07 ± 6.7 mg/dL. Overall 60.5 % of ovarian cancer survivors enrolled in LIVES demonstrate hyperlipidemia, including 202 (51.8%) with elevated total cholesterol and 119 (30.5%) with elevated triglycerides. There is indication that 26.9% of the sample have elevated glucose concentrations consistent with pre-diabetes. Additionally, the prevalence of inflammation, as assessed using hsCRP as a non-specific marker, is high with 68.0% of the ovarian cancer survivors enrolled having a level above 3.0 mg/dL.Conclusions: Future assessments will include repeat measures of these cardiometabolic biomarkers over time (6, 12 and 24 months post study enrollment) as well as change in these biomarkers in relation to intervention group assignment and adherence to the lifestyle intervention. When completed the LIVES study will be the largest lifestyle intervention ever completed among survivors of ovarian cancer.
Keywords: Ovarian Cancer, diet, physical activity, cardiometabolic biomarkers